Why MaxCyte, Inc.’s (MXCT) Stock Is Up 28.47%
As of Wednesday, October 14, MaxCyte, Inc.’s MXCT share price has surged by 28.47%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 29.63%
As of Wednesday, October 14, MaxCyte, Inc.’s MXCT share price has surged by 29.63%, which has investors questioning if this is right time to sell.Omar Beirat
Why MaxCyte, Inc.’s (MXCT) Stock Is Down 5.92%
As of Tuesday, October 13, MaxCyte, Inc.’s MXCT share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MaxCyte, Inc.’s (MXCT) Stock Is Down 5.38%
As of Thursday, October 08, MaxCyte, Inc.’s MXCT share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Michael Rose
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 5.12%
As of Wednesday, August 19, MaxCyte, Inc.’s MXCT share price has surged by 5.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $134.2 | $3,670.7 | 25% |
|
| Shares Out (Mil) | 106.8 | 101.8 | 63% |
|
| Institutional Ownership | 98.0% | 88.3% | 76% |
|
| Float (Mil) | 93.7 | 79.7 | 59% |
|
| Beta | 1.49 | 1.19 | 82% |
|
| Avg Daily Volume (000s) | 2,030 | 928 | 82% |
|
| Price Change (52-week) |
(26.6%) | 83.2% | 32% |
|
| Growth | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.7% | 7.5% | 35% |
|
| Net Income (5yr) | (30.5%) | (11.2%) | 13% |
|
| EPS (5yr) | (19.8%) | 2.5% | 14 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (27.7%) | (14.9%) | 22% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.083) | ($0.277) | ($0.247) | |
| Month Ago EPS | ($0.083) | ($0.277) | ($0.247) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.077) | ($0.277) | ($0.233) | |
| Year/Year Chg | 0.0% | (33.9%) | (42.7%) | |
| Financials | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $31 | $800 | 16% |
|
| Net Income (TTM) (Mil) | ($36) | ($32) | 19% |
|
| EPS (TTM) | ($0.334) | ($0.300) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | $47 | 14% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $6 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $263 | 31% |
|
| Enterprise Value (Q1) (Mil) | $48 | $3,587 | 16% |
|
| Valuation | MXCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.87 | 3.60 | 21% |
|
| P/E | na | 42.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.3 | na |
|
| Ratios | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.2% | 47.7% | 88% |
|
| Net Margin | (114.8%) | (6.0%) | 7% |
|
| ROA | (17.6%) | (4.8%) | 21% |
|
| ROE | (20.4%) | (7.9%) | 23% |
|
| Liabilities to Assets | 14.0% | 41.0% | 9% |
|
| F-Score | 3 | 5 | 18% |
|
MaxCyte, Inc. did not pass any screens on 10/19/2026.
